Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.

作者：Douglas A. Arenberg, Michael P. Keane, Bruno DiGiovine, Steven L. Kunkel, Susan B. Morris, Ying Xue, Marie D. Burdick, Mary Glass, Mark D. Iannettoni, Robert M. Strieter · 发表于：Journal of Clinical Investigation · 年份：1998 · DOI：10.1172/jci3145 · 被引用次数：259 · 研究领域：Cell Adhesion Molecules Research、Chemokine receptors and signaling、Peptidase Inhibition and Analysis

We report here the role of the CXC chemokine, epithelial neutrophil activating peptide (ENA-78), as an angiogenic factor in human non-small cell lung cancer (NSCLC). In freshly isolated human specimens of NSCLC, elevated levels of ENA-78 were found that strongly correlated with the vascularity of the tumors. In a SCID mouse model of human NSCLC tumorigenesis, expression of ENA-78 in developing tumors correlated with tumor growth in two different NSCLC cell lines. Furthermore, passive immunization of NSCLC tumor-bearing mice with neutralizing anti-ENA-78 antibodies reduced tumor growth, tumor vascularity, and spontaneous metastases, while having no effect on the proliferation of NSCLC cells either in vitro or in vivo. These findings suggest that ENA-78 is an important angiogenic factor in human NSCLC.